Generic drug market in Central Europe will grow by 6% per annum between 2011 and 2013
In 2010, the generic drug market in Central Europe increased in value by 12%, whereas that of original medicines grew at a rate of around 10% in euro terms, according to information contained in the latest report by Poland-based market research and consulting firm PMR, titled Generic and innovative drug market in Central Europe 2011.
In 2011 and 2012, the trends which boosted generic sales in 2010, including price pressure and other restrictive measures, will continue. This is why the generic market will develop more rapidly than its original counterpart during these years.
Generic growth rate will exceed that of originals
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze